Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure.
Despite ethnic differences in heart failure prevalence, risk profiles, and outcomes, no clinical trials have been designed to prospectively examine the mechanisms responsible for these differences. The African-American Heart Failure Trial is the first prospective trial designed to test a novel therapy that enhances endothelial function and nitric oxide bioavailability in African-American patients with advanced heart failure.
University of Minnesota Medical School,420 Delaware Street S.E., MMC 293, Minneapolis, MN 55455, USA. taylo135@umn.edu
Anne L
AL
Taylor
D000328:Adult; D001741:Black or African American; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology / Q000627:therapeutic use*; D007547:Isosorbide / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000502:physiology*; D011446:Prospective Studies; D016896:Treatment Outcome
D006830:Hydralazine; D009569:Nitric Oxide; D007547:Isosorbide